Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man
- PMID: 3382587
- PMCID: PMC1387802
- DOI: 10.1111/j.1365-2125.1988.tb03324.x
Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man
Abstract
1. The effects of the acute and chronic administration of the alpha 1-adrenoceptor antagonist alfuzosin (5 mg twice daily for 7 days) on baroreflex function, physiological tremor and sedation (visual analogue scale) were investigated in six healthy volunteers. 2. Phenylephrine-systolic pressure dose-response curves were shifted (P less than 0.05) to the right by alfuzosin compared with placebo on day 1, and on day 8 prior to the administration of alfuzosin indicating significant alpha-adrenoceptor blockade over 24 h with 5 mg twice daily administration. 3. Baroreflex sensitivity (delta R-R ms mmHg-1 systolic arterial pressure) was reduced (P less than 0.05) by alfuzosin compared with placebo on day 1 (13.8 +/- 2.6 vs 20.6 +/- 3.6 ms mmHg-1) and on day 8 (13.4 +/- 1.7 vs 21.1 +/- 2.7 ms mmHg-1). 4. Maximum power (microV2) or frequency (Hz) of physiological tremor did not change 2 h after alfuzosin administration on day 1 (13.7 +/- 4.4 microV2, 9.2 +/- 0.3 Hz) or day 8 (11.5 +/- 4.3 microV2, 10.0 +/- 0.4 Hz) compared with placebo on day 1 (16.9 +/- 7.5 microV2, 10.0 +/- 0.4 Hz) and day 8 (17.3 +/- 5.7 microV2, 10.2 +/- 0.8 Hz). 5. Alfuzosin 5 mg twice daily did not cause sedation on day 1 or day 8. 6. In conclusion the reduction in baroreflex sensitivity with the alpha-adrenoceptor antagonist alfuzosin may contribute to its antihypertensive activity in reducing the reflex tachycardia associated with its hypotensive action.
Similar articles
-
Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.Eur J Clin Pharmacol. 1989;37(1):53-8. doi: 10.1007/BF00609425. Eur J Clin Pharmacol. 1989. PMID: 2591463 Clinical Trial.
-
Effect of acute and chronic indoramin administration on baroreflex function and tremor in humans.J Cardiovasc Pharmacol. 1988 Mar;11(3):284-90. doi: 10.1097/00005344-198803000-00004. J Cardiovasc Pharmacol. 1988. PMID: 2452920 Clinical Trial.
-
Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man.Br J Clin Pharmacol. 1985 Nov;20(5):431-6. doi: 10.1111/j.1365-2125.1985.tb05093.x. Br J Clin Pharmacol. 1985. PMID: 2866788 Free PMC article. Clinical Trial.
-
Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.Drugs. 1993 Mar;45(3):410-29. doi: 10.2165/00003495-199345030-00008. Drugs. 1993. PMID: 7682910 Review.
-
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.Drugs. 2002;62(4):633-53. doi: 10.2165/00003495-200262040-00009. Drugs. 2002. PMID: 11893233 Review.
Cited by
-
Effect of UK-52,046, an alpha 1-adrenoceptor antagonist, on baroreflex function in man.Br J Clin Pharmacol. 1990 Oct;30(4):579-84. doi: 10.1111/j.1365-2125.1990.tb03816.x. Br J Clin Pharmacol. 1990. PMID: 1981319 Free PMC article. Clinical Trial.
-
Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.Eur J Clin Pharmacol. 1989;37(1):53-8. doi: 10.1007/BF00609425. Eur J Clin Pharmacol. 1989. PMID: 2591463 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical